JPWO2021016640A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021016640A5 JPWO2021016640A5 JP2022504582A JP2022504582A JPWO2021016640A5 JP WO2021016640 A5 JPWO2021016640 A5 JP WO2021016640A5 JP 2022504582 A JP2022504582 A JP 2022504582A JP 2022504582 A JP2022504582 A JP 2022504582A JP WO2021016640 A5 JPWO2021016640 A5 JP WO2021016640A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- optionally
- subunit
- tumor
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878574P | 2019-07-25 | 2019-07-25 | |
| US62/878,574 | 2019-07-25 | ||
| PCT/US2020/070308 WO2021016640A1 (en) | 2019-07-25 | 2020-07-24 | Compositions and methods comprising protease-activated therapeutic agents |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022542886A JP2022542886A (ja) | 2022-10-07 |
| JP2022542886A5 JP2022542886A5 (https=) | 2023-08-02 |
| JPWO2021016640A5 true JPWO2021016640A5 (https=) | 2023-08-02 |
| JP7682150B2 JP7682150B2 (ja) | 2025-05-23 |
Family
ID=74194303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504582A Active JP7682150B2 (ja) | 2019-07-25 | 2020-07-24 | プロテアーゼ活性化治療剤を含む組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220281936A1 (https=) |
| EP (1) | EP4003401A4 (https=) |
| JP (1) | JP7682150B2 (https=) |
| CN (1) | CN114466657B (https=) |
| AU (1) | AU2020316002A1 (https=) |
| BR (1) | BR112022001320A2 (https=) |
| CA (1) | CA3148621A1 (https=) |
| MX (1) | MX2022000991A (https=) |
| WO (1) | WO2021016640A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| US20240228586A1 (en) * | 2021-05-07 | 2024-07-11 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| JP2024527582A (ja) | 2021-07-19 | 2024-07-25 | 中外製薬株式会社 | 融合ポリペプチドを用いるプロテアーゼ媒介性の標的特異的サイトカイン送達 |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| WO2023050826A1 (en) * | 2021-09-28 | 2023-04-06 | Suzhou Fuse Biosciences Limited | Immunoconjugates containing tnf-alpha and related methods and compositions thereof |
| KR102609822B1 (ko) * | 2021-10-05 | 2023-12-06 | (주)케어젠 | 항염증 활성을 갖는 펩타이드와 이의 용도 |
| JP2024539139A (ja) | 2021-10-20 | 2024-10-28 | シンセカイン インコーポレイテッド | ヘテロ二量体ｆｃサイトカインおよびその使用 |
| CN113995855A (zh) * | 2021-11-10 | 2022-02-01 | 中国药科大学 | 一种抗纤维化纳米载体和纳米制剂及其制备方法 |
| CN114272390B (zh) * | 2021-12-29 | 2022-09-02 | 中山大学附属第一医院 | 一种微环境靶向联合细胞靶向肿瘤抑制载体及其制备方法和应用 |
| EP4619420A1 (en) | 2022-11-16 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Chimeric proteins comprising membrane bound il-12 with protease cleavable linkers |
| CN119060196A (zh) * | 2023-05-31 | 2024-12-03 | 郑州大学 | 一种金属蛋白酶激活型car-t结构的制备及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0638644A1 (en) * | 1993-07-19 | 1995-02-15 | F. Hoffmann-La Roche Ag | Receptors of interleukin-12 and antibodies |
| US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| JP4793971B2 (ja) * | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| EP3263581B2 (en) * | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| US20090325200A1 (en) * | 2006-03-24 | 2009-12-31 | Beck William T | Polypyrimidine-tract binding protein (ptb) as a biomarker and target for the diagnosis and treatment of cancer |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| TWI759810B (zh) * | 2014-08-08 | 2022-04-01 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CA3018145C (en) * | 2016-03-18 | 2024-09-17 | Geistlich Pharma Ag | TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER |
| CN118307682A (zh) * | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| WO2018184003A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon |
| WO2018218231A1 (en) * | 2017-05-25 | 2018-11-29 | The Broad Institute, Inc. | Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof |
| CN111050803A (zh) * | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
| CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| CA3100005A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN112867503A (zh) * | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
| US20240228586A1 (en) * | 2021-05-07 | 2024-07-11 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
-
2020
- 2020-07-24 MX MX2022000991A patent/MX2022000991A/es unknown
- 2020-07-24 JP JP2022504582A patent/JP7682150B2/ja active Active
- 2020-07-24 CA CA3148621A patent/CA3148621A1/en active Pending
- 2020-07-24 EP EP20844027.1A patent/EP4003401A4/en active Pending
- 2020-07-24 WO PCT/US2020/070308 patent/WO2021016640A1/en not_active Ceased
- 2020-07-24 US US17/597,793 patent/US20220281936A1/en active Pending
- 2020-07-24 CN CN202080067433.2A patent/CN114466657B/zh active Active
- 2020-07-24 BR BR112022001320A patent/BR112022001320A2/pt unknown
- 2020-07-24 AU AU2020316002A patent/AU2020316002A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021016640A5 (https=) | ||
| Schönherr et al. | Decorin core protein fragment Leu155-Val260 interacts with TGF-β but does not compete for decorin binding to type I collagen | |
| Blasig et al. | On the self-association potential of transmembrane tight junction proteins | |
| Ruoslahti et al. | Alignment of biologically active domains in the fibronectin molecule. | |
| Tschopp et al. | Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. | |
| US20200048331A1 (en) | Immunoregulatory structures from normally occuring proteins | |
| RU2013110876A (ru) | Активируемые биспецифические антитела | |
| WO2021092075A1 (en) | IL-2RβγC BINDING COMPOUNDS | |
| CN105744944B (zh) | 免疫系统调节器 | |
| RU2714154C2 (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| CA2289912A1 (en) | Human receptor proteins; related reagents and methods | |
| CA2386463A1 (en) | April receptor (bcma) and uses thereof | |
| Avery et al. | Characterization of factor H binding to human polymorphonuclear leukocytes. | |
| CN116655799A (zh) | 包括可切割接头的il-2细胞因子前药 | |
| KR20220093323A (ko) | HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료 | |
| JPWO2022236292A5 (https=) | ||
| AU672967B2 (en) | Polypeptides with fibronectin binding sites as modulators for matrix assembly | |
| KR101974583B1 (ko) | 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법 | |
| Fisher et al. | Affinity labelling of the binding site of rabbit antibody. Evidence for the involvement of the hypervariable regions of the heavy chain | |
| KR20250164808A (ko) | Gprc5d에 결합하는 나노바디 및 이의 용도 | |
| WO2024003393A1 (en) | Fusion proteins with half life extending domains | |
| CN114269791B (zh) | 用于治疗体液免疫抑制疾病的体液免疫抑制拮抗剂的组合物和用途 | |
| Duk et al. | Identification of an epitope recognized by the monoclonal antibody PEP80 in the C-terminal cytoplasmic fragment of glycophorin A | |
| JPWO2020247974A5 (https=) | ||
| Miranda et al. | Heterologous expression of Homo sapiens alpha-folate receptors in E. coli by fusion with a trigger factor for enhanced solubilization |